Incident Cases Captured in the National Cancer Database Compared with Those in U.S. Population Based Central Cancer Registries in 2012–2014

Mallin, Katherine; Browner, Amanda; Palis, Bryan E.; McCabe, Ryan; Nogueira, Letícia; Yabroff, K. Robin; Shulman, Lawrence N.; Facktor, Matthew A.; Winchester, David P.; Nelson, Heidi

doi:10.1245/s10434-019-07213-1

Cited by 283 publications

(239 citation statements)

References 3 publications

Supporting

Mentioning

226

Contrasting

Order By: Relevance

“…While the NCDB captures over 70% of cancer cases diagnosed in the US, inclusion of some racial/ethnic minority groups, such as AIs/ANs and HAs, as well as kidney cancer cases in the Mountain and Pacific states, especially Arizona is lower. 24,25 Reported cases for some Hispanic subgroups, particularly Dominicans, in the NCDB, were not very large. Therefore, the findings from the NCDB may not be generalizable.…”

Section: Discussionmentioning

confidence: 95%

“…The data includes cases from health care systems that tend to be larger in size, and it has low coverages for AIs/ANs and HAs as well as kidney cancer cases in the Mountain and Pacific states, especially Arizona. 24,25 The ACR is a population-based surveillance system. The ACR data include AI kidney cancer cases reported from the Indian Health Service (IHS) facilities in Arizona, that are not included in the NCDB.…”

Section: Renal Cell Carcinoma Case Datamentioning

confidence: 99%

See 1 more Smart Citation

Racial/ethnic disparities in renal cell carcinoma: Increased risk of early‐onset and variation in histologic subtypes

et al. 2019

View full text Add to dashboard Cite

Background Racial/ethnic minority groups have a higher burden of renal cell carcinoma (RCC), but RCC among Hispanic Americans (HAs) and American Indians and Alaska Natives (AIs/ANs) are clinically not well characterized. We explored variations in age at diagnosis and frequencies of RCC histologic subtypes across racial/ethnic groups and Hispanic subgroups using National Cancer Database (NCDB) and Arizona Cancer Registry Data. Methods Adult RCC cases with known race/ethnicity were included. Logistic regression analysis was performed to estimate odds and 95% confidence interval (CI) of early‐onset (age at diagnosis <50 years) and diagnosis with clear cell RCC (ccRCC) or papillary RCC. Results A total of 405 073 RCC cases from NCDB and 9751 cases from ACR were identified and included. In both datasets, patients from racial/ethnic minority groups had a younger age at diagnosis than non‐Hispanic White (NHW) patients. In the NCDB, AIs/ANs had twofold increased odds (OR, 2.21; 95% CI, 1.88‐2.59) of early‐onset RCC compared with NHWs. HAs also had twofold increased odds of early‐onset RCC (OR, 2.14; 95% CI, 1.79‐2.55) in the ACR. In NCDB, ccRCC was more prevalent in AIs (86.3%) and Mexican Americans (83.5%) than NHWs (72.5%). AIs/ANs had twofold increased odds of diagnosis with ccRCC (OR, 2.18; 95% CI, 1.85‐2.58) in the NCDB, but the association was stronger in the ACR (OR, 2.83; 95% CI, 2.08‐3.85). Similarly, Mexican Americans had significantly increased odds of diagnosis with ccRCC (OR, 2.00; 95% CI, 1.78‐2.23) in the NCDB. Conclusions This study reports younger age at diagnosis and higher frequencies of ccRCC histologic subtype in AIs/ANs and Hispanic subgroups. These variations across racial/ethnic groups and Hispanic subgroups may have potential clinical implications.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Renal Cell Carcinoma Case Datamentioning

confidence: 99%

Racial/ethnic disparities in renal cell carcinoma: Increased risk of early‐onset and variation in histologic subtypes

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Initial treatment data obtained from the National Cancer Data Base (NCDB) are provided for breast cancer cases diagnosed in 2016 and were previously presented in Cancer treatment and survivorship statistics, 2019 in this journal . The NCDB is a hospital‐based cancer registry jointly sponsored by the American Cancer Society and the American College of Surgeons and includes greater than 70% of all invasive cancers in the United States from more than 1500 facilities accredited by the American College of Surgeons' Commission on Cancer . Data on chemotherapy include targeted therapy and immunotherapies because many common targeted therapies are classified as chemotherapy in the NCDB.…”

Section: Methodsmentioning

confidence: 99%

Breast cancer statistics, 2019

DeSantis

Gaudet

et al. 2019

CA A Cancer J Clinicians

2,540

1,881

View full text Add to dashboard Cite

This article is the American Cancer Society’s biennial update on female breast cancer statistics in the United States, including data on incidence, mortality, survival, and screening. Over the most recent 5‐year period (2012‐2016), the breast cancer incidence rate increased slightly by 0.3% per year, largely because of rising rates of local stage and hormone receptor‐positive disease. In contrast, the breast cancer death rate continues to decline, dropping 40% from 1989 to 2017 and translating to 375,900 breast cancer deaths averted. Notably, the pace of the decline has slowed from an annual decrease of 1.9% during 1998 through 2011 to 1.3% during 2011 through 2017, largely driven by the trend in white women. Consequently, the black–white disparity in breast cancer mortality has remained stable since 2011 after widening over the past 3 decades. Nevertheless, the death rate remains 40% higher in blacks (28.4 vs 20.3 deaths per 100,000) despite a lower incidence rate (126.7 vs 130.8); this disparity is magnified among black women aged <50 years, who have a death rate double that of whites. In the most recent 5‐year period (2013‐2017), the death rate declined in Hispanics (2.1% per year), blacks (1.5%), whites (1.0%), and Asians/Pacific Islanders (0.8%) but was stable in American Indians/Alaska Natives. However, by state, breast cancer mortality rates are no longer declining in Nebraska overall; in Colorado and Wisconsin in black women; and in Nebraska, Texas, and Virginia in white women. Breast cancer was the leading cause of cancer death in women (surpassing lung cancer) in four Southern and two Midwestern states among blacks and in Utah among whites during 2016‐2017. Declines in breast cancer mortality could be accelerated by expanding access to high‐quality prevention, early detection, and treatment services to all women.

show abstract

“…Hospital‐based cancer registries, such as the National Cancer Database (NCDB), offer an alternative to some of the limitations of SEER and SEER‐Medicare data. The NCDB collects standardized data on the first course of treatment, in addition to patient, tumor, and facility characteristics, for approximately 70% of all new invasive cancer diagnoses in the United States . The NCDB started collecting data on receipt of immunotherapy in 2013.…”

Section: Changes In Receipt Of Systemic Treatment For Select Cancers mentioning

confidence: 99%

“…The NCDB collects standardized data on the first course of treatment, in addition to patient, tumor, and facility characteristics, for approximately 70% of all new invasive cancer diagnoses in the United States. 20,21 The NCDB started collecting data on receipt of immunotherapy in 2013. NCDB data show an increase in the receipt of systemic treatment for some (breast, bladder, and pancreatic), but not all, of the cancers included in the study ( Table 1).…”

mentioning

confidence: 99%